Skip to content

Study · Case report or series · n = 1 · 2023

2 results

Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis-Related Cirrhosis With Liraglutide.

Yuen C, Yu T, French S, Marcus EA, Yeh J, Chiu H

JPGN reports30 Mar 2023Cited by 1 (Europe PMC)

PMID37200728 (opens in a new tab)PMCIDPMC10187831 (opens in a new tab)DOI10.1097/pg9.0000000000000303 (opens in a new tab)PepBankPUB-37200728
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Nonalcoholic fatty liver disease is the most common chronic liver disease in children in the United States and encompasses a range of disease from steatosis to cirrhosis. The mainstay of treatment is lifestyle modifications like increased physical activity and healthier eating habits. These are sometimes augmented with medications or surgery for weight loss. We present a patient with biopsy-proven nonalcoholic steatohepatitis-related cirrhosis that did not improve with suboptimal lifestyle changes. This patient's disease progression reversed after liraglutide treatment, as evidenced by improved imaging and laboratory results, despite no significant improvement in her body mass index percentile. This case demonstrates the importance of considering liraglutide for patients with nonalcoholic steatohepatitis and suggests a hepatic effect independent of effects related to weight loss.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an adolescent with NASH-related cirrhosis, disease progression reversed after liraglutide treatment, with improved imaging and laboratory results.

    In plain wordsIn one adolescent with NASH-related cirrhosis, liver disease reversed after liraglutide, with better imaging and lab results.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver disease progression (imaging and laboratory results)
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This patient's disease progression reversed after liraglutide treatment, as evidenced by improved imaging and laboratory results
    1 context sentence
    Summary · context
    We present a patient with biopsy-proven nonalcoholic steatohepatitis-related cirrhosis that did not improve with suboptimal lifestyle changes.
  2. 02HumanCase report or seriesEfficacy outcome

    In an adolescent with NASH-related cirrhosis, liraglutide treatment was not accompanied by a significant improvement in BMI percentile.

    In plain wordsIn one adolescent with NASH-related cirrhosis, BMI percentile did not improve significantly on liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeBMI percentile
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    despite no significant improvement in her body mass index percentile.
    1 context sentence
    Summary · context
    We present a patient with biopsy-proven nonalcoholic steatohepatitis-related cirrhosis that did not improve with suboptimal lifestyle changes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.